Lipid-lowering benefits on clinical outcomes relative to baseline LDL value
KEY POINT
A meta-analysis published in JAMA of 34 trials involving more than 270,000 patients showed that more intensive LDL-lowering therapy compared with less-intensive therapy resulted in a greater reduction in the risk of all-cause and cardiovascular (CV) mortality, but only in patients with baseline LDL levels of 100 mg/dL or more.
SOURCES
Navarese EP, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA. 2018;319(15):1566–79.
Navar AM, et al. Challenges in interpreting the lipid-lowering trials: Biology vs. ecology. JAMA. 2018;319(15):1549–51.
